Bioeureka™ and IVADO: A Strategic Alliance for AI-Assisted Pathogen Diagnosis

Montreal, June 16, 2026 — IVADO, one of Canada’s leading artificial intelligence (AI) consortia, and Bioeureka™, a pioneer in the development of next-generation microbiological diagnostic solutions, today announced the formation of a landmark partnership. Together, the two organizations are committed to breaking new ground in the rapid and accurate identification of pathogens : a breakthrough with the potential to transform global public health.

A Collaboration at the Intersection of Biotechnology and AI

This partnership is rooted in a shared vision: to harness the power of AI to profoundly transform the diagnosis of infections. At a time when pathogen threats are evolving faster than ever, the ability to accurately and rapidly identify infectious agents is a critical challenge for both clinicians and public health authorities.

As a pioneer in the development of next-generation microbiological diagnostic solutions, Bioeureka™ is committed to integrating AI and molecular biology to enable rapid, accurate, and accessible identification of infectious pathogens.

With its recognized expertise in data science, machine learning, and applied research, IVADO will provide Bioeureka™ with an exceptional framework to accelerate the development and validation of its identification algorithms.

The Leaders’ Vision

“Our partnership with IVADO is not just a technological validation—it’s a statement of intent. We are convinced that AI is the key that will unlock a new era in microbiological diagnostics. By partnering with one of the world’s leading AI ecosystems, we are accelerating our ability to protect lives. This partnership amplifies every goal we’ve been pursuing and propels us far beyond our initial horizons. It is our deep conviction that Bioeureka™ and IVADO will together redefine what it means to diagnose quickly and accurately.” — CEO of Bioeureka™, Founder and Chief Executive Officer, Bioeureka™

“With IVADO, we have access to unparalleled AI resources and expertise. This allows us to train models that are more robust, more interpretable, and above all—more reliable under real-world conditions. This isn’t just a research partnership: it’s the engine that will propel our product pipeline to a whole new level. I’m incredibly excited about what we’ll accomplish together in the coming months.” — Zoé Ducourau, AI Product Manager, Bioeureka™

A strategic milestone on the path to growth

This collaboration marks a decisive step in Bioeureka™’s technological and strategic maturation. With its technological credibility strengthened by successive collaborations with leading institutions, the company will be supported by IVADO in ambitious applied research projects, where it will benefit from direct access to the latest advances in deep learning and the processing of complex biological data, as well as to a network of world-class experts.

By supporting Bioeureka™ on its path of accelerated growth, IVADO reaffirms its role as the strategic partner of choice for companies seeking to integrate the most advanced AI technologies into their operations, drawing on the best available resources to ensure that innovation is rigorous, reproducible, and value-creating.

About Bioeureka™

Bioeureka™ is an innovative company in the field of biotechnology applied to microbiological diagnostics. Its mission is to develop next-generation diagnostic tools that integrate artificial intelligence and molecular biology to enable rapid, accurate, and accessible identification of infectious pathogens.

About IVADO

IVADO is an interdisciplinary and cross-sectoral consortium dedicated to research, training, knowledge transfer, and knowledge mobilization, with a mission to build and promote robust, reasoning, and responsible artificial intelligence. Led by the Université de Montréal, with four academic partners (Polytechnique Montréal, HEC Montréal, Université Laval, and McGill University), IVADO brings together research centers, government partners, and industry partners to collaboratively develop ambitious cross-sector initiatives that foster a paradigm shift in AI and its adoption.